Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 502

1.

Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burtt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sánchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1973-81.

2.

Haplotypes of the estrogen receptor beta gene and breast cancer risk.

Breast and Prostate Cancer Cohort Consortium, Cox DG, Bretsky P, Kraft P, Pharoah P, Albanes D, Altshuler D, Amiano P, Berglund G, Boeing H, Buring J, Burtt N, Calle EE, Canzian F, Chanock S, Clavel-Chapelon F, Colditz GA, Feigelson HS, Haiman CA, Hankinson SE, Hirschhorn J, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, LeMarchand L, Lund E, Palli D, Peeters PH, Pike MC, Riboli E, Stram DO, Thun M, Tjonneland A, Travis RC, Trichopoulos D, Yeager M.

Int J Cancer. 2008 Jan 15;122(2):387-92.

3.

Estrogen receptor beta polymorphism is associated with prostate cancer risk.

Thellenberg-Karlsson C, Lindström S, Malmer B, Wiklund F, Augustsson-Bälter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K, Gustafsson JA, Grönberg H.

Clin Cancer Res. 2006 Mar 15;12(6):1936-41.

4.

Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.

Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1993-7.

5.

Comprehensive evaluation of ESR2 variation and ovarian cancer risk.

Leigh Pearce C, Near AM, Butler JL, Van Den Berg D, Bretsky P, Conti DV, Stram DO, Pike MC, Hirschhorn JN, Wu AH.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):393-6. doi: 10.1158/1055-9965.EPI-07-2512.

6.

Genetic variation in the HSD17B1 gene and risk of prostate cancer.

Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, Hayes RB, Altshuler D, Andriole G, Berg C, Boeing H, Burtt NP, Bueno-de-Mesquita B, Calle EE, Cann H, Canzian F, Chen YC, Crawford DE, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Gonzalez CA, Haiman CA, Hallmans G, Henderson BE, Hirschhorn JN, Hunter DJ, Kaaks R, Key T, Le Marchand L, Ma J, Overvad K, Palli D, Pike MC, Riboli E, Rodriguez C, Setiawan WV, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Trichopoulou A, Virtamo J, Wacholder S.

PLoS Genet. 2005 Nov;1(5):e68. Epub 2005 Nov 25.

7.

Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.

Cheng I, Stram DO, Penney KL, Pike M, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML.

J Natl Cancer Inst. 2006 Jan 18;98(2):123-34.

PMID:
16418515
8.

CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.

Travis RC, Schumacher F, Hirschhorn JN, Kraft P, Allen NE, Albanes D, Berglund G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Calle EE, Chanock S, Dunning AM, Hayes R, Feigelson HS, Gaziano JM, Giovannucci E, Haiman CA, Henderson BE, Kaaks R, Kolonel LN, Ma J, Rodriguez L, Riboli E, Stampfer M, Stram DO, Thun MJ, Tjønneland A, Trichopoulos D, Vineis P, Virtamo J, Le Marchand L, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2734-44. doi: 10.1158/1055-9965.EPI-09-0496. Epub 2009 Sep 29.

9.

IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).

Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; Breast and Prostate Cancer Cohort Consortium.

PLoS One. 2008 Jul 2;3(7):e2578. doi: 10.1371/journal.pone.0002578.

10.

CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2237-46.

11.

A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk.

Yu KD, Rao NY, Chen AX, Fan L, Yang C, Shao ZM.

Breast Cancer Res Treat. 2011 Feb;126(1):37-45. doi: 10.1007/s10549-010-0891-2.

PMID:
20390341
12.

Common genetic variation at PTEN and risk of sporadic breast and prostate cancer.

Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, Penney K, Le Marchand L, Henderson BE, Freedman ML.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1021-5.

13.

Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.

Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson JE, Li G, Adami HO, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Grönberg H.

J Natl Cancer Inst. 2005 Apr 6;97(7):525-32.

PMID:
15812078
14.

Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3).

Canzian F, Kaaks R, Cox DG, Henderson KD, Henderson BE, Berg C, Bingham S, Boeing H, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Dossus L, Feigelson HS, Haiman CA, Hankinson SE, Hoover R, Hunter DJ, Isaacs C, Lenner P, Lund E, Overvad K, Palli D, Pearce CL, Quiros JR, Riboli E, Stram DO, Thomas G, Thun MJ, Trichopoulos D, van Gils CH, Ziegler RG.

BMC Cancer. 2009 Jul 29;9:257. doi: 10.1186/1471-2407-9-257.

15.

Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies.

Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burtt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, Peeters PH, Pike MC, Riboli E, Setiawan VW, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D.

Cancer Res. 2006 Feb 15;66(4):2468-75. Erratum in: Cancer Res. 2008 May 1;68(9):3550.

16.

Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer.

Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K.

PLoS One. 2009 Aug 5;4(8):e6523. doi: 10.1371/journal.pone.0006523.

17.

Estrogen receptor genotypes and haplotypes associated with breast cancer risk.

Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K.

Cancer Res. 2004 Dec 15;64(24):8891-900.

18.

Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer.

Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1990-9.

19.

A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.

Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO.

BMC Med Genet. 2007 Dec 1;8:72.

20.

Comprehensive assessment of genetic variation of catechol-O-methyltransferase and breast cancer risk.

Gaudet MM, Chanock S, Lissowska J, Berndt SI, Peplonska B, Brinton LA, Welch R, Yeager M, Bardin-Mikolajczak A, Garcia-Closas M.

Cancer Res. 2006 Oct 1;66(19):9781-5.

Supplemental Content

Support Center